University of Texas System

Other

Regeneron Pharmaceuticals, Inc.

Dnatrix, Inc.

Juan Fueyo

Candelaria Gomez-Manzano

Charles A Conrad

W K Alfred Yung

Frederick Lang, Jr

Jesse M Cedarbaum

Jocelyn Holash

Wk Alfred Yung

Candeleria Manzano-Gomez

Fred Lang

The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

Oncolytic adenovirus armed with therapeutic genes

A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.

Infectivity-enhanced conditionally-replicative adenovirus and uses thereof

Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

Use of VEGF antagonists for the treatment of malignant gliomas

Growing community of inventors

Houston, TX, United States of America

Juan Fueyo